Purdue Pharma Announces Risk Strategy for ButransTM

Working with the Food and Drug Administration (FDA), Purdue Pharma L.P. has announced the development of a Risk Evaluation and Mitigation Strategy (REMS) for Butrans(tm) (buprenorphine) Transdermal System.   

The goals of the Butrans REMS Program are:

1. To inform patients and healthcare professionals about the potential for abuse, misuse, and overdose from, and addiction to Butrans; and
2. To inform patients and healthcare professionals about the safe use of Butrans

For more idetails visit www.butransrems.com<http://www.butransrems.com> which provides important information for healthcare professionals as well as patients and caregivers.